Sep. 28 at 3:04 PM
$MOVE I looked at the 10Q, declining sales and declining infrastructure costs, it looks like a company that is putting all its resources into appearing as sexy as possible for a potential buyer. Actualy, they no longer have a choice, they absolutely must find a buyer to survive, but they have assets with their non-invasive blood pressure measurement system, even if it is not yet fully validated by the FDA, given the current valuation of the company it could be a very good deal for a big player in the smartwatch sector. At this level, there is little point in looking at the graph (even if precursor signals can give us indications) we just have to wait for the PR which gives us the conditions of the buyout. 🤷🏻♂️
It's a poker move to try, either it works or it breaks 🤞
